Industry News

Russia Approves AmBisome and DaunoXome

Published in AIDS Weekly, August 18th, 1997

NeXstar Pharmaceuticals, Inc., Boulder, Colorado, announced that the Russian Ministry of Health granted marketing approval for its two proprietary liposomal products, AmBisome and DaunoXome.

The Russian Ministry of Health approved AmBisome, the company's liposomal antifungal drug, as a first line treatment in adults and infants for the treatment of severe systemic fungal infections, including fever of unknown origin (FUO), candidiasis, cryptococcosis, cryptococcal meningitis, aspergillosis, and histoplasmosis. AmBisome now is approved by regulatory authorities for sale in 28 countries throughout the world.

DaunoXome was approved for the treatment of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1997-08-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry